However, only limited information has been reported on viral shedding after RV-TV vaccination.

Reduced viral shedding was associated with reduced serum antibody responses.

Parameters studied included serological responses, and clinical disease and nasal viral shedding following challenge infection.

Dental treatment did not influence asymptomatic viral shedding patterns.

Morbidity and mortality rates, as well as viral shedding, were investigated as parameters of virus infection.

Tissue samples were obtained to evaluate for gene transfer, generation of wild-type virus, viral shedding, and antibody response.

Three patients (25%) had recurrent viral shedding after treatment, but none of these relapsed with invasive infections.

We report the clinical characteristics, viral shedding duration, and contact tracing for asymptomatic carriers of SARS-CoV-2 in Wuhan, China.

These data show that the durations of disease and viral shedding of caliciviruses are longer than has been described elsewhere.

Conclusions: TIV was not observed to ameliorate clinical symptoms or viral shedding among vaccine failures compared with infected placebo recipients.

The median viral shedding duration was 11.5 days.

However, reduced severity of disease and viral shedding have also been linked to antibodies targeting the second viral surface glycoprotein, the neuraminidase.

Lower antibody response might have explained vaccine failure and also lack of effect in reducing clinical symptoms and viral shedding upon infection.

In this patient, the course of disease and duration of viral shedding was apparently prolonged, thus highlighting the need for increased infection control.

Thus, both simultaneous and sequential inoculations of susceptible adults with CR influenza vaccine viruses result in reduced viral shedding and serum antibody responses.

Notably, 2 months of viral shedding duration were reported in two nurses, which was much longer than previously reported or than usually thought.